中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HC359236 |
|---|---|
| 설명 |
Anti-Human CD47 Reference Antibody (STI-6643, RUO) (HC359236) is a human monoclonal antibody detecting CD47.
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG |
| 클론 ID | STI-6643 |
| 생물학적 활성 | STI-6643 binds to human CD47 with a K d of 76 nM, with lower affinity for cynomolgus (177 nM) and canine (134 nM) CD47 antigens [1]. STI-6643 (25 min) binds dose-dependently to human MDA-MB-231 (EC 50 ~30.0 ug/mL), human RAJI (EC 50 6.64 ug/mL), canine OSCA-40 (EC 50 ~30.0 ug/mL), and canine OSCA-78 (EC 50 ~30.0 ug/mL) cancer cells [1]. STI-6643 (0.09-200 ug/mL; 15 min) dose-dependently blocks the CD47/SIRPα interaction on human CCRF-CEM cells with an IC 50 of 3.65 ug/mL, without reaching saturation at concentrations up to 200 ug/mL [1]. STI-6643 (0.0001-10 ug/mL; 30 min) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells [1]. STI-6643 (1.5625-50 ug/mL) does not exhibit direct tumor cell killing activity on human CCRF-CEM leukemia cells [1]. STI-6643 (100 ug/mL; 25 min) exhibits negligible binding to human (EC 50 = 11.76 ug/mL) and cynomolgus monkey (EC 50 = 20.32 ug/mL) RBCs, with slightly stronger binding to canine RBCs (EC 50 = 5.10 ug/mL) [1]. STI-6643 (0.001-300 ug/mL; 20 h) does not induce hemagglutination of human or cynomolgus monkey RBCs at concentrations up to 300 ug/mL, and exhibits weak, 100-fold less potent hemagglutination activity than Hu5F9 in canine RBCs [1]. STI-6643 (0.001-100 ug/mL; 3 days) preserves human T cell survival and functionality in a superantigen stimulation assay, with minimal impact on IFN-γ secretion [1]. STI-6643 (0.001-500 ug/mL; 6 days) preserves the survival of human CD4+, CD8+, CD19+, and CD56+ immune cells [1]. STI-6643 (2.5-5 ng/mL; 30 min) in combination with Rituximab () enhances macrophage-mediated phagocytosis of human RAJI-GFP cells [1]. STI-6643 (0.1-60 mg/kg; i.v.; 3x/week; 2 consecutive weeks) exhibits potent dose-dependent anti-tumor activity and survival benefits in a mouse disseminated Burkitt's lymphoma xenograft model [1]. STI-6643 (20 mg/kg; i.v. |
| 타겟 | Antigenic surface determinant protein OA3, CD47, IAP, Integrin-associated protein, Leukocyte surface antigen CD47, MER6, Protein MER6 |
| 내독소 수준 | < 10 EU/mg as determined by LAL method. |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q08722 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | STI-6643, STI6643, STI6643 |
| 배경 | Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 11509594 2. Piccio, L. et al. (2005) Blood 105, 2421-7. PMID: 15383453 3. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 19004835 4. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 7691831 5. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 8550562 6. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 7. Ghimire, K. et al. (2020) Cells 9. PMID: 32679764 |
| 참고 문헌 | 1. Thaker YR, et al. A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. Front Oncol. 2022;12:884196. Published 2022 May 19. [HC359236] 2. Xu S, et al. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Front Immunol. 2023 May 29;14:1199631. [HC359236] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Anti-Human CD47/MER6 (STI-6643)
문의하기
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
